Knowledge HQ

The case study illustrates ScaleReady's effective use of technology and tailored strategies to overcome AgonOx's challenges. Through detailed analysis and strategic implementation of ScaleReady technology, analytics, and automation, ScaleReady achieved significant improvements in customer satisfaction and operational efficiency.  

TcBuster-MTM (TcB-MTM) is a commercially available non-viral transposase-based editing platform that overcomes current viral limitations. TcBuster is found in the red flour beetle and is a member of the hAT family of transposases. Using directed evolution, we engineered a hyperactive mutant (TcB-M) that has improved transposition rates using less mRNA transposase and NanoplasmidTM DNA transposon.

Current iNK differentiation protocols typically utilize xenogenic feeder cells, which could be problematic for patient safety, or they lack robustness and are highly variable in differentiation efficiency. Using animal-free small molecules and recombinant proteins, Bio-Techne developed a feeder-free differentiation process to reliably generate iNKs at scale by optimizing for CD34+ hematopoietic stem cells (iHSC) prior to downstream NK differentiation.

Aliquot accuracy whitepaper provides an in-depth look at how the Cue® Cell Processing System ensures consistency and quality in cell therapy products.

Download the ExCellerate NK Media Feeder-Cell G-Rex Culture Process

Download the protocol to support a feeder-free process in G-Rex cell culture.

ExCellerate NK Media offers a robust and versatile solution for NK cell cultures, designed to transition from research to clinical application seamlessly.

Utilization of G-Rex by introducing a new scalable depletion method: Coculturing target CAR T cells with an NK-92 cell line in G-Rex to purify their CAR T cells and promote CAR T cell expansion at the same time.

This scientific poster presented at CIMT 2023 investigates glioblastoma, a WHO grade IV glioma and the most common primary adult brain tumor, and the expression of elevated levels of HLA-E that block NK cells with expression of the inhibitory NKG2A receptor, aiming to establish a large-scale ex vivo expansion of functional NKG2C+ NK cells.  Doing so from peripheral blood employing bottom-gas permeable membrane bioreactors (G-Rex) and using a recently developed PC-3 feeder cell line genetically engineered with IL-2, membrane-bound IL-15, as well as a first generation single chain trimeric HLA-E molecule.

Join Anastasiya Smith, Snr. Director of R&D at Marker Therapeutics for a 15-minute pre-recorded webinar covering the first critical steps in successful automation through simplification with the G-Rex platform.

This is our proven process illustrating how ScaleReady works in a true partnership with your T and NK cell therapy program to enable the successful commercialization of your drug. This is a linear left-to-right, as well as a holistic view, of how at every stage, we look to simplify, streamline, and scale by offering expertise and support for your cell therapy program. Through our proven process, we deliver practical and viable solutions by providing the most simple, scalable, and versatile manufacturing products. Our process is proven, as our products are represented in approved CAR-T drugs around the globe.